JENNIFER BEAULIEU: Open Payments
NPI 1477258341 · PAYETTE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$965 in 23 payments from 7 companies in 2025. Trend: 2023 $21 · 2024 $585 · 2025 $965
Food & beverage: $874Education: $91
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $237 |
| Otsuka America Pharmaceutical, Inc. | 2 | $210 |
| ABBVIE INC. | 13 | $174 |
| E.R. Squibb & Sons, L.L.C. | 1 | $127 |
| Teva Pharmaceuticals USA, Inc. | 2 | $115 |
| Alkermes, Inc. | 1 | $87 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: VRAYLAR, INGREZZA, COBENFY, REXULTI, ABILIFY MAINTENA, LYBALVI, AUSTEDO XR, BREZTRI.
Industry payments across ID — which companies pay providers there.
